Pregnancy and Accelerated Phase of Myeloid Chronic Leukemia Treated with Imatinib: A Case Report from a Developing Country.
Background. Chronic myeloid leukemia is a hematological malignancy caused by expression of BCR-ABL tyrosine kinase oncogene, product of the t(9;22) Philadelphia translocation. Accelerated phase of this disease marks the onset of advanced rapidly progressive disease unresponsive to many therapies. Pregnancy limits broad number of therapies on patients because of their potential teratogenic effects. We report the case of a pregnant 34-year-old patient on accelerated phase successively managed by imatinib. She achieved a safe pregnancy and delivered at 39 weeks a healthy baby without congenital abnormalities. Our case is unusual because of the accelerated phase of the disease. Case Presentation. A 34-year-old African female with history of chronic phase of myeloid leukemia on imatinib, lost to follow-up for 4 months, presented to the hematological department for abdominal discomfort. Accelerated phase of chronic myeloid leukemia was diagnosed. Complete hematological response was achieved on high doses of imatinib. At the completion of 39 weeks, she delivered a healthy child without congenital anomalies. Conclusion. Despite its teratogenic and embryotoxic effects, front line imatinib is the only effective, well-tolerated treatment for patient on accelerated phase that can be offered to patients in sub-Saharan countries.
Department of Medical Hematology, Brazzaville Teaching Hospital, 13 Avenue Auxence Ikonga, BP 32, Brazzaville, Congo.
Lydie Ocini
LO
Ngolet
Department of Medical Hematology, Brazzaville Teaching Hospital, 13 Avenue Auxence Ikonga, BP 32, Brazzaville, Congo.
Innocent
I
Kocko
Department of Medical Hematology, Brazzaville Teaching Hospital, 13 Avenue Auxence Ikonga, BP 32, Brazzaville, Congo.
Alexis
A
Elira Dokekias